Schizophrenia | Disease Landscape & Forecast | G7 | 2024
The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of atypical antipsychotics influences psychiatrists’ treatment decisions, newer oral agents (e.g., Intra-Cellular Therapies’ Caplyta) are aiming to make inroads into the treatment pathway. Competition between LAIs is also intensifying with the availability of new therapies (e.g., Lundbeck / Otsuka’s Abilify Asimtufii, Teva’s Uzedy), along with the generic availability of some key LAIs. Nevertheless, novel drugs targeting key unmet needs will be welcomed (e.g., Bristol Myers Squibb’s Cobenfy for partial responders, Boehringer Ingelheim’s iclepertin for cognitive impairment) if they clearly differentiate themselves from established therapies to gain a strong foothold in this market. As such, a deep understanding of the current and future dynamics of the schizophrenia therapy market is critical.
Questions answered
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What factors drive and constrain the use of newer-to-market oral and LAIs of atypical antipsychotics? How is competition heating up in these segments?
- What are the areas of highest unmet need in schizophrenia treatment?
- What improvements would key late-phase therapies need to demonstrate to compete effectively in this market? How will these agents be placed in the schizophrenia treatment algorithm?
Content highlights
Release date: December 2024. Updated throughout the year to reflect Clarivate’s expert analysis of the latest major-market events
Geographies: United States, EU5, Japan.
Primary research: 33 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research
Epidemiology: Prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; diagnosed / drug-treated prevalence of schizophrenia by country
Forecast: 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2033, segmented by brands / generics
Emerging therapies: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
